Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay
Standard
Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. / Alix-Panabières, Catherine; Pantel, Klaus.
In: EXPERT REV MOL DIAGN, Vol. 15, No. 11, 11.2015, p. 1411-7.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay
AU - Alix-Panabières, Catherine
AU - Pantel, Klaus
PY - 2015/11
Y1 - 2015/11
N2 - Circulating tumor cells (CTCs) in the blood of cancer patients have received increasing attention as new diagnostic tool enabling 'liquid biopsies'. In contrast to the wealth of descriptive studies demonstrating the clinical relevance of CTCs as biomarkers, the extremely low concentration of CTCs in the peripheral blood of most cancer patients challenges further functional studies. This article discusses the current possibilities to enrich and, in particular, detect viable CTCs with emphasis on the EPithelial ImmunoSPOT technology. This functional assay detects viable CTCs at the single-cell level and has been used on hundreds of patients with different tumor types including epithelial tumors (breast, prostate and colon cancer) and melanomas. Moreover, the article summarizes recent advances in the in vitro and in vivo expansion of CTCs from cancer patients. These functional analyses will contribute to identifying the biological properties of metastatic cells and reveal new therapeutic targets against disseminating cancer cells.
AB - Circulating tumor cells (CTCs) in the blood of cancer patients have received increasing attention as new diagnostic tool enabling 'liquid biopsies'. In contrast to the wealth of descriptive studies demonstrating the clinical relevance of CTCs as biomarkers, the extremely low concentration of CTCs in the peripheral blood of most cancer patients challenges further functional studies. This article discusses the current possibilities to enrich and, in particular, detect viable CTCs with emphasis on the EPithelial ImmunoSPOT technology. This functional assay detects viable CTCs at the single-cell level and has been used on hundreds of patients with different tumor types including epithelial tumors (breast, prostate and colon cancer) and melanomas. Moreover, the article summarizes recent advances in the in vitro and in vivo expansion of CTCs from cancer patients. These functional analyses will contribute to identifying the biological properties of metastatic cells and reveal new therapeutic targets against disseminating cancer cells.
U2 - 10.1586/14737159.2015.1091729
DO - 10.1586/14737159.2015.1091729
M3 - SCORING: Journal article
C2 - 26390240
VL - 15
SP - 1411
EP - 1417
JO - EXPERT REV MOL DIAGN
JF - EXPERT REV MOL DIAGN
SN - 1473-7159
IS - 11
ER -